NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.
Frederick J KohlhappJoseph R BroucekTasha HughesErica J HuelsmannJevgenijs LusciksJanet P ZayasHubert DolubiznoVidyaratna A FleetwoodAlisa GrinGraham E HillJoseph L PoshepnyArman NabatiyanCarl E RubyJoshua D SnookJai S RudraJason M SchenkelDavid MasopustAndrew ZlozaHoward L KaufmanPublished in: Journal for immunotherapy of cancer (2015)
These results have implications for the design of clinical trials in patients with metastatic melanoma and provide new insights into how the immune system may be mediating anti-tumor activity with combination IL-2 and CTLA-4 blockade in melanoma.